fbpx

News

Lundbeckfonden Ventures News

BURLINGTON, Mass. – July 1, 2020 – scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that it has resubmitted its 505(b)(2) New Drug Application (NDA) to the U.S. Food and...
Acacia Pharma Announces US FDA Approval of BYFAVO™ (remimazolam) for injection for the Induction and Maintenance of Procedural Sedation   BYFAVO is a very rapid onset/offset IV benzodiazepine sedative for use during invasive medical procedures lasting 30 minutes or less, such as colonoscopy and bronchoscopy Approximately 25 million such procedures take place annually in the...
Lead ‘OncoMimics’ candidate EO2401 planned to start first clinical trials for Glioblastoma and Adrenal Tumors during mid-2020 Paris, France and Cambridge, MA, USA – June 25, 2020 ENTEROME SA, a clinical-stage biopharmaceutical company leveraging its unique knowledge  of the microbiome-immunoinflammation axis to develop next-generation therapeutics, today announces a new financing totaling €46.3 million ($52.6million) to...
SNF472 selectively inhibits pathological calcification by binding to hydroxyapatite crystals Palma, Spain and San Diego, USA, 25 June 2020 – Sanifit, a clinical-stage biopharmaceutical company focused on developing treatments for calcification disorders, today announced that data examining the mechanism of action of SNF472, Sanifit’s lead compound in development, has been published in the British Journal of...
•    The EU bank will support Palma-based Sanifit in its work to develop cutting-edge solutions in biomedical research. •    The venture debt operation is supported by the Investment Plan for Europe. Palma, Spain and San Diego, USA, 6 August 2020 – The European Investment Bank (EIB) is set to support the development of new treatments...
Newly appointed VP of Business Development and SVP of Clinical Development each bring to Sanifit over 20 years of industry experience Palma, Spain and San Diego, USA, 01 June 2020 – Sanifit, a clinical-stage biopharmaceutical company focused on developing treatments for calcification disorders, is delighted to announce two new appointments to its Executive leadership team, with...
Cambridge, UK and Indianapolis, US –  1 June 2020: Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a commercial-stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures or chemotherapy, announces an amendment to the terms...
Paris, France and Cambridge, MA, USA – August 5, 2020   ENTEROME SA, a clinical-stage biopharmaceutical company leveraging its unique knowledge of the microbiome-immunoinflammation axis to develop next-generation therapeutics, announces that Pierre Belichard, CEO, and Christophe Bonny, CSO, will participate in the BTIG Virtual Biotechnology Conference 2020 which will take place August 10-11th 2020.  ...
Cambridge, UK and Indianapolis, US – 8 May 2020: Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer chemotherapy, announces...
1 2 3 4 5 68

Lundbeckfonden Ventures

News

Enterome announces first patient dosed in Phase 2a trial of sibofimloc in Crohn’s disease
23. September 2020
Aura Biosciences Announces Dosing of First Patient in Phase 2 Study Evaluating Suprachoroidal Administration of AU-011 in Patients with Choroidal Melanoma
11. September 2020
Enterome – First Patient Dosed in a Phase 1/2 Trial with EO2401, an Innovative ‘OncoMimic’ based Immunotherapy Candidate Targeting Adrenal Tumors
9. September 2020